Form 4: Fortress Biotech: CFO Receives Restricted Stock Units

Fortress Biotech's Chief Financial Officer, David Jin, was granted 400,000 restricted stock units as part of his compensation.

Summary

• David Jin, Chief Financial Officer of Fortress Biotech, Inc., received an award of 400,000 restricted stock units (RSUs) on June 22, 2026.
• These RSUs represent a contingent right to receive one share of the company's common stock.
• The RSUs will vest in four equal annual installments, starting January 5, 2027, contingent upon Jin's continued service.
• Upon vesting, the RSUs will be settled in shares of Fortress Biotech's common stock.
• Following this award, Jin's total beneficial ownership of common stock is 1,651,571 shares, which includes 1,230,000 shares from previously granted deferred RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development.

Positives

• The company is incentivizing its Chief Financial Officer with equity awards, aligning his interests with shareholders.
• The grant of 400,000 RSUs indicates a commitment to retaining key executive talent.
• The vesting schedule over four years suggests a long-term retention strategy.

Negatives

• The filing does not provide details on the performance metrics or conditions tied to the vesting of these RSUs beyond continued service.
• The value of the award is not explicitly stated, making it difficult to assess its full financial impact on the executive's compensation.

Risks

• The value of the restricted stock units is subject to market fluctuations in Fortress Biotech's common stock price.
• If David Jin's service is terminated before vesting, the unvested RSUs will be forfeited, potentially impacting the company's financial planning and executive retention.

Future Outlook

The future outlook related to this filing is primarily centered on the vesting of the restricted stock units awarded to the CFO, which will occur in installments over four years, subject to continued service. The settlement of these units will result in the issuance of additional shares of common stock.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units, is a common practice in the biotechnology sector to attract and retain executive talent, especially given the long development cycles and inherent risks in drug discovery and development.

Stakeholder Impact

• Shareholders: Potential dilution of ownership due to the issuance of shares upon vesting of RSUs. However, it also signals executive commitment.
• Employees: May be seen as a positive sign of executive retention and company stability.
• Management: Reinforces the compensation structure for key executives.

Next Steps

• Vesting of restricted stock units in four equal annual installments starting January 5, 2027.
• Settlement of vested restricted stock units in shares of Fortress Biotech's common stock.

Key Dates

Keywords

Fortress Biotech, FBIO, Form 4, Restricted Stock Units, RSU, Executive Compensation, David Jin, Chief Financial Officer, Stock Award, Beneficial Ownership